Pharma Groups Back Pfizer In 3rd Circ. Pay-For-Delay Case

By Dani Kass (March 29, 2016, 4:39 PM EDT) -- Pharmaceutical groups on Monday asked the Third Circuit not to revive claims that Pfizer Inc. illegally paid Ranbaxy Laboratories Inc. to postpone its generic of cholesterol drug Lipitor, arguing that all agreements were legal under the U.S. Supreme Court's Actavis decision and that the retailers bringing the suit lacked evidence....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!